Reversal effects of desipramine on resistance of U251/TR cells to temozolomide

MA Jian*,YANG Yan-ru*,LIU Jing-jing,LI Fang-fang,CHEN Mei-hua,WANG Hao, WANG Lei,SUN Li-li,WANG Feng-ze,WANG De-cai,Han-ting ZHANG，3

(1.Institute of Pharmacology,2.School of Life Science,Taishan Medical College,Taian 271016,China;3.Departments of Behavioral Medicine&Psychiatry and Physiology&Pharmacology,West Virginia University College of Medicine,Morgantown,WV 26506，USA)

·ORIGINAL ARTICLES·

Reversal effects of desipramine on resistance of U251/TR cells to temozolomide

MA Jian1*,YANG Yan-ru1*,LIU Jing-jing1,LI Fang-fang1,CHEN Mei-hua1,WANG Hao1, WANG Lei1,SUN Li-li1,WANG Feng-ze2,WANG De-cai1,Han-ting ZHANG1，3

(1.Institute of Pharmacology,2.School of Life Science,Taishan Medical College,Taian 271016,China;3.Departments of Behavioral Medicine&Psychiatry and Physiology&Pharmacology,West Virginia University College of Medicine,Morgantown,WV 26506，USA)

OBJECTIVETo examine the reversal effect of desipramine(DMI)on resistance to temozolomide(TMZ)in U251/TR cells and explore its mechanism.METHODSU251/TR cells were exposed to DMI(20-80 μmol·L-1)or TMZ(0.5-10 mmol·L-1)for 24 h,cell viability was determined by cell counting kit-8 assay with IC50calculated.The cytotoxicity of U251/TR cells treated with TMZ(1 or 2 mmol·L-1)in combination with DMI(20,30 or 40 μmol·L-1)for 24 h was detected using CCK-8 assay.Synergism between DMI and TMZ was analyzed by the JIN Zheng-jun method.Apoptosis of U251/TR cells induced by TMZ 1 mmol·L-1,DMI 30 μmol·L-1,or their combination was examined by Hoechst33258 stains and caspase 3 activity was detected by luminescence analysis.Expression of C/EBP homologous protein (CHOP)was measured using quantitative real-time PCR and Western blotting.The survival rate of U251/TR cells treated with TMZ 1 mmol·L-1and/or DMI 30 μmol·L-1was also assessed after silencing CHOP expression by small interference RNA(siRNA).RESULTSDMI or TMZ alone inhibited the growth of U251/TR cells significantly in a concentration-dependent manner(r2=0.983,0.982,P<0.05), with the IC50(33.6±0.5)μmol·L-1and(2.5±0.6)mmol·L-1,respectively.The cell viability inhibitory rate of U251/TR cells by TMZ(1 or 2 mmol·L-1)combined with DMI(20,30,or 40 μmol·L-1)was greater than that by TMZ or DMI alone(P<0.05).The JIN Zheng-jun analysis revealed that combination of DMI and TMZ produced synergistic cytotoxicity(Q>1.15),ie,compared with TMZ alone,TMZ(1 mmol·L-1)com?bined with DMI(30 μmol·L-1)produced significant nuclear fragmentation and condensation(P<0.05). In addition,DMI and TMZ in combination activated caspase 3 activity in U251/TR cells(P<0.05).Knock?down of CHOP by specific siRNA attenuated the synergistic effect of DMI in the presence of TMZ,the survival rate of the combined drug group raised from 51.8%to 62.2%(P<0.05).CONCLUSIONThe results suggest that DMI reverse resistance of U251/TR cells to TMZ through activation of the CHOP-depend?ently apoptosis pathway.

glioma;desipramine;temozolomide;drug resistance;C/EBP homologous protein

Glioma is the most common and primary malignant brain tumor[1].However,glioma is difficult to be resected completely in surgery because of the special location.As a result,the current standard therapy for glioma is surgical resection followed by radiotherapy plus concomitant chemotherapy. Temozolomide (TMZ)is the mosteffective chemotherapeutic agent for treatment of glioma[2]. However,the efficacy of glioma treatment is severely reduced by the resistance to TMZ.It is of importance to develop therapeutic approaches to overcome this issue.A large number of preclinical and clinical studies have been carried out attempting to find drugs that can enhance the efficacy of TMZ[3-5].One example is the combined use of antidepressants[6-7]. Clinical studies have demonstrated that depressive disorders are common comorbidity in patients with advanced cancer,leading to the use of antide?pressants as conventional adjuvant agents in treatment of cancer comorbid with depression[8-9]. The direct biological effects of antidepressant drugs on tumor cells have attracted much attention in recent years.Desipramine(DMI),a classic antidepressant of TCAs,improves the mood of patients with depressive disorders.It also exerts various off-target effects such as analgesic and antitumor actions[10-11].DMI has been reported to inhibitcancer cellproliferation and induce apoptosis[12-13].Our previous study has also demonstrated that DMI induces apoptosis of glioma C6 cells[14].In the present study,we investigated the ability of DMI to reverse drug resistance to TMZ in the U251/TR glioma cellline and explored the related mechanisms.

1 MATERIALS AND METHODS

1.1 Drugs

DMI and TMZ were purchased from Sigma-Aldrich(St.Louis,MO,USA).The antibody against CHOP was purchased from Cell Signaling Technology(Danvers,MA,USA),whilethe antibody against β-actin and horseradish peroxidaseconjugated anti-mouse or anti-rabbit IgG were from Santa Cruz Biotechnology(Santa Cruz,CA, USA).

1.2 Cell culture

U251 cells were purchased from the Chinese Academy of Sciences Cell Bank(Shanghai,China). The U251/TR cell line was induced by the stepwise revulsion with TMZ.U251/TR cells were cultured in Dulbecco′s modified Eagle′s medium(DMEM)( (Invitrogen,Carlsbad,CA),supplemented with 10% fetal bovine serum (Invitrogen,Carlsbad, CA)and 1%penicillin/streptomycin(Invitrogen, Carlsbad,CA),and maintained in a humidified in?cubator with 5%CO2at 37℃.

1.3 CCK-8 assay for detection of cell viability

The viability of cells was analyzed by cell counting kit-8(CCK-8)kit(Dojindo Laboratories,Ku?mamoto,Japan).U251/TR cells were seeded on a 96-well plate at a density of 5000 cells/well and were cultured overnight.Various concentrations of DMI(20,30,40,50,60,70,or 80 μmol·L-1),TMZ (0.5,0.7,1,3,5,7,or 10 mmol·L-1),or the com?bination of TMZ(1 or 2 mmol·L-1)and DMI(20, 30 or 40 μmol·L-1)were then added to the wells and cultured for 24 h.Cell viability was assessed following the procedures described in the manu?facturer′s instructions.

1.4 Hoechst33258 staining for observation of cell apoptosis

U251/TR cells(1×105per well)were seeded on sterile cover glasses placed in the six-well plates and cultured overnight.The cells were then exposed to DMI 30 μmol·L-1+TMZ 1 mmol·L-1for 24 h,after which cells were fixed and washed twice with phosphate-buffer saline(PBS)and stained with Hoechst 33258 staining for 1 h(Bey?otime,Jiangsu,China).Stained nuclei were ob?served under a confocal microscope(Leica,Hei?delberg,Germany).

1.5Luminescence analysisof caspase 3 activity

U251/TR cells(3000 per well)were seeded on a 96-well microplate and incubated with DMI 30 μmol·L-1+TMZ 1 mmol·L-1for 24 h,followed by mixing with 100 μL of Caspase-Glo?3/7 Reagent(Promega,Madison,USA)at room tem?perature for 1 h.The luminescence intensities were analyzed with Multimode Reader (Tecan, M?nnedorf,Switzerland);enzyme activity was ex?pressed as a relative luminescence unit.

1.6 Quantitative real-time(RT-PCR)for deter?mining CHOP expression

U251/TR cells(5×105per well)were cultured on a 6-well plate and exposed to DMI(30 μmol·L-1) and TMZ(1 mmol·L-1)for 24 h.Total RNA extraction was isolated from cells by using RNAprep Pure Cell/Bacteria Kit(Tiangen,Beijing,China). The first strand cDNA synthesis was carried out using Quantscript RT cDNA Kit(Tiangen,Beijing, China).The RT mixture was mixed with Real Master Mix(SYBR green)agent(Tiangen,Beijing, China)and gene-specific primers in a final volume of 20 μL.Primers used for human CHOP were 5′-GAAACGGAAACAGAGTGGTCATTCCCC-3′and 5′-GTGGGATTGAGGGTCACATCATTGGCA-3′; for human β-actin were 5′-AGACGCAGGATG?GCATGGG-3′and 5′-GAGACCTTCAACACCCCAGCC-3′.The quantitative real-time RT-PCR was determined in ABI 7500 fast Real Time PCR (Life Technologies,CA,USA)using the following amplification conditions:hold for 2 min at 95℃, followed by 40 cycles of 95℃ for 30 s,60℃ for 20 s and 68℃ for 60 s.Data are expressed as the fold differences in target gene expression compared with both the endogenous control gene expression and the calibrator,using the 2-△△Ctmethod.

1.7 Western blotting analysis for detection of CHOP expression

U251/TR cells(5×105per well)were cultured on a 6-well plate overnight.Cells were incubated with DMI(30 μmol·L-1)and TMZ(1 mmol·L-1)for 24 h,followed by washing with ice-cold 1×PBS for twice and lysed cells in cold RIPA buffer. Identical amounts of cell lysates were separated by 10%or 12%SDS-PAGE,and proteins were electro-transferred onto PVDF membranes(Millipore, Bedford,MA,USA).Membraneswerethen incubated in blocking buffer(5%nonfat milk in TBS containing 0.1%Tween 20)at room temper?ature for 2 h.After washing in TBST buffer〔10 mmol·L-1Tris-HCl(pH 8.3),0.05%Tween-20 (Sigma Ultra,St.Louis,MO,USA)〕,membranes were incubated with primary antibodies against CHOP(1∶1000)and β-actin(1∶1000)as the control at 4℃ overnight before incubating with HRP-conjugated secondary antibodies(1∶5000, Zhongshan,Beijing,China)at room temperature for 2 h.The signal was visualized by chemilumi?nescence detection kit(Pierce Chemical,Rock?ford,IL,USA).

1.8 Small interference RNA(siRNA)experiments

The CHOP-specific siRNAs-(5′-GCUAGCUGAAGAGAAUGAATT-3′and 5′-UUCAUUCU?CUUCAGCUAGCTT-3′),scrambled siRNA(5′-UUCUCCGAACGUGUCACGUTT-3′and 5′-AC?GUGACACGUUCGGAGAATT-3′and negative control)were designed and synthesized by GenePharma(GenePharma,Shanghai,China). For transfection,cells were plated in a 12-well plate or a 96-well plate overnight before trans?fecting with siRNAs using Lipofectamine 2000 (Invitrogen Life Technologies,Carlsbad,CA) after 60%confluence was achieved.The knock?down effect was measured by quantitative realtime RT-PCR.Cells were then incubated with DMI 30 μmol·L-1+TMZ 1 mmol·L-1for 24 h,and then washed with medium before CCK-8 assays.

1.9 Statistical analysis

Data are presented asx±sand were analyzed by analysis ofvariances(ANOVA) followed by Dunnett′sttest,whereP<0.05 indicated a significantdifference.Synergistic analysis is presented with Q value,which was calculated by the JIN Zheng-jun method[15].Q>1.15 represents synergism,Q=0.85-1.15 addition, and Q<0.85 antagonism.

2 RESULTS

2.1 Effects of DMI and/or TMZ on U251/TR cell viability

As shown in Fig.1,DMI(20-80 μmol·L-1)or TMZ(0.5-10 mmol·L-1)treatment alone for 24 h reduced cellviability,as demonstrated by concentration-dependent inhibition of cell proliferation(Fig.1A,B);the IC50was(33.6±0.5)μmol·L-1for DMI and(2.5±0.6)mmol·L-1for TMZ.To examine the potential synergistic cytotoxicity,U251/TR cells were treated with lower concentrations of DMI (20,30 and 40 μmol·L-1)and TMZ(1 and 2 mmol·L-1)for 24 h,either alone or in combination. The combination of DMI and TMZ at certain concentrations produced remarkable potentiation in decreasing viability of U251/TR cells(P<0.05) (Fig.1C).Synergistic analysis is presented with Q values(Tab.1).It was observed that combination of DMI and TMZ produced a significant synergistic effect with the Q value>1.15.

Fig.1 Effect of desipramine(DMI)and temozolomide (TMZ)on U251/TR cell viability.U251/TR cells were exposed to DMI，TMZ，or their combination for 24 h.x±s，n=3.**P<0.01，compared with corresponding normal control group；#P<0.05，compared with corresponding TMZ alone group；△P<0.05，compared with corresponding DMI alone group.

Tab.1 Q values of combined administration of DMI and TMZ

2.2 Effects of DMI and/or TMZ on U251/TR apoptosis

Fig.2 showed that DMI(30 μmol·L-1)or TMZ (1 mmol·L-1)treatment alone for 24 h produced remarkable morphological changes in U251/TR cells.The nuclear size of U251/TR cells was decreased and the Hoechst fluorescence intensity in nuclei was increased,indicating the typical phenotype of apoptosis.In combination treatment, the morphological changes in nuclei of U251/TR cells were even more pronounced.

Fig.2 Effect of TMZ and DMI alone or in combination on U251/TR cell morphological changes by laser scanning confocal microscope. U251/TR cells were exposed to TMZ(1 mmol·L-1)，DMI(30 μmol·L-1)，or both for 24 h.

2.3 Effects of DMI and/or TMZ on caspase 3 activity of U251/TR cells

As shown in Fig.3,after treatment with DMI(30 μmol·L-1)or TMZ(1 mmol·L-1)alone, caspase 3 activity in U251/TR cells was signifi?cantly increased.This effect was further potentiated by combination of both treatments(P<0.05).

Fig.3 Effect of TMZ and DMI alone or in combination on caspase 3 activity of U251/TR cell.See Fig.2 for the treatment.x±s，n=3.**P<0.01，compared with normal control group；#P<0.05，compared with DMI alone group；△P<0.05，compared with TMZ alone group.

2.4Effects of DMIand/or TMZ on CHOP mRNA and protein expression in U251/TR cells

Treatment with DMI(30 μmol·L-1)or TMZ (1 mmol·L-1)alone robustly upregulated CHOP mRNAs in U251/TR cells(Fig.4);protein expression of CHOP was concomitantly increased following DMI or TMZ treatment(Fig.5).The effects of TMZ on CHOP mRNA or protein levels were markedly potentiated in the presence of DMI(P<0.05).

2.5 Effects of DMI and/or TMZ on CHOP-specific siRNA transfected U251/TR cell viability

Fig.4 Effect of TMZ and DMI alone or in combination for 24 h on CHOP mRNA expression in U251/TR cells detected by quantitative real-time RT-PCR.x±s，n=3.*P<0.05，compared with DMI alone；#P<0.05，compared with TMZ alone.

Fig.5 Effect of TMZ and DMI alone or in combination for 24 h on CHOP protein expression in U251/TR cells by Western blotting.B was the semi-quantitative result of A.x±s，n=3.*P<0.05，compared with normal control group；#P<0.05，compared with DMI alone group；△P<0.05，compared with TMZ alone group.

To further determine whether CHOP was involved in the synergistic effect of the combination treatment,CHOP expression was silenced by CHOP-specific siRNAs.The mRNA level of CHOP in U251/TR cells was significantly reduced to 19.2%by transfection of CHOP specific siRNAs. The survival rate of the combined drug group raised from 51.8%to 62.2%(P<0.05)after CHOP knockdown by CHOP-specific siRNA(Fig.6). These results suggest thatDMI increase sensitivity of glioma cells to TMZ by activating CHOP.

Fig.6 Effect of TMZ or DMI alone or in combination on survival of U251/TR cells after CHOP knockdown by CHOP-specific siRNAs(si-CHOP).U251/TR cells were firstly transfected with CHOP-specific siRNAs or scrambled siRNAs (si-SCR)for 24 h，respectively.Cells were then exposed to DMI and/or TMZ for another 24 h，after which the survival rate of U251/TR cells was detected by CCK-8 assays.x±s，n=3.**P< 0.01，compared with corresponding si-SCR group.

3 DISCUSSION

In the present study,DMI synergistically enhanced TMZ-induced inhibition of proliferation. The synergistic effect appears to be involved by apoptosis,which may be triggered by the combined treatment with DMI and TMZ,as demonstrated by confocal microscopy.Following the treatment with both DMI and TMZ,U251/TR cells showed typical,apoptotic,morphological changes such as nuclear shrinkage and DNA condensation. This is supported by synergistic increases in caspase 3 activity produced by combination of both drugs.

CHOP,a crucial regulator of ER stress-related apoptosis signaling,plays an important role in DMI-induced apoptosis[14].In the present study, we demonstrated that combination of both DMI and TMZ synergistically activated CHOP expression in U251/TR cells in terms of CHOP mRNA and protein.In addition,knockdown of CHOP abrogated the synergistic effect of DMI in the presence of TMZ,suggesting that DMI enhances the apoptotic effect of TMZ through activation of CHOP.This is consistent with our previous study[14],which demonstrates that CHOP plays a key role in apoptosis induced by DMI in C6 glioma cells.

In conclusion,DMIsynergistically enhances the antitumor action of TMZ through activation of CHOP,as demonstrated in U251/TR cells.The results suggest that combination of DMI and TMZ can be a promising option for treatment of patients with glioma,in particular those with comorbidity of depression.

REFERENCES:

［1］Mrugala MM.Advances and challenges in the treatment of glioblastoma:a clinician′s perspective［J］.Discov Med,2013,15(83):221-230.

［2］Stupp R,Hegi ME,Mason WP,Van Den Bent MJ, Taphoorn MJ,Janzer RC,et al.Effects of radio?therapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phaseⅢstudy:5-year analysis of the EORTC-NCIC trial［J］.Lancet Oncol,2009,10 (5):459-466.

［3］Zhang Y,Ma JW,Liu HY,Wang SX,Yan YR,Liu ZH,et al.Inhibitory effect of temozolomide com?bined with tetrandrine on human glioblastoma U87 cells［J］.Chin J Pharmacol Toxicol(中國藥理學與毒理學雜志),2014,28(3):367-372.

［4］ Nitta Y,Shimizu S,Shishido-Hara Y,Suzuki K, Shiokawa Y,Nagane M.Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo［J］.Cancer Med,2016,5(3):486-499.

［5］Yu Z,Zhao G,Xie G,Zhao L,Chen Y,Yu H,et al. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo［J］.Oncotarget,2015,6(32): 32930-32943.

［6］Song T,Li H,Tian Z,Xu C,Liu J,Guo Y.Disruption of NF-κB signaling by fluoxetine attenuates MGMT ex?pression in glioma cells［J］.Onco Targets Ther, 2015,20(8):2199-2208.

［7］Qi H,Chen HZ,Feng JM,Jin ZJ.Effect of desipra?mine alone and in combination with teniposide on proliferation in rat C6 glioma cells［J］.China Oncol(中國癌癥雜志),2000,10(1):62-64.

［8］Goldzweig G,Hasson-Ohayon I,Alon S,Shalit E. Perceived threat and depression among patients with cancer:the moderating role of health locus of control［J］.Psychol Health Med,2016,21(5):601-607.

［9］BarberB,Dergousoff J,Slater L,Harris J, O′connell D,El-Hakim H,et al.Depression and survival in patients with head and neck cancer:a systematic review［J］.JAMA Otolaryngol Head Neck Surg,2016,142(3):284-288.

［10］ Mika J,Zychowska M,Makuch W,Rojewska E, Przewlocka B.Neuronal and immunological basis of action of antidepressants in chronic pain-clinical and experimental studies［J］.Pharmacol Rep,2013, 65(6):1611-1621.

［11］Qi H,Chen HZ,Jin ZJ.Effect of desipramine on proliferation,inhibition and apoptosis induction in rat glioma C6 cells［J］.Acta Pharmacol Sin,2002,23 (9):803-807.

［12］Kinjo T,Kowalczyk P,Kowalczyk M,Walaszek Z, Slaga TJ,Hanausek M.Effects of desipramine on the cell cycle and apoptosis in Ca3/7 mouse skin squamous carcinoma cells［J］.Int J Mol Med,2010, 25(6):861-867.

［13］Chang HC,Huang CC,Huang CJ,Cheng JS,Liu SI,Tsai JY,et al.Desipramine-induced apoptosis in human PC3 prostate cancer cells:activation of JNK kinase and caspase 3 pathways and a protective role of［Ca2+］ielevation［J］.Toxicology,2008,250 (1):9-14.

［14］Ma J,Qiu Y,Yang L,Peng L,Xia Z,Hou LN,et al. Desipramine induces apoptosis in ratglioma cells via endoplasmic reticulum stress-dependent CHOP pathway［J］.J Neurooncol,2011,101(1):41-48.

［15］Jin ZJ.Addition in drug combination［J］.Acta Pharmacol Sin(中國藥理學報),1980,1(1):70-76.

地昔帕明逆轉人腦膠質瘤耐藥細胞U251/TR對替莫唑胺的耐藥作用

馬 健1*，楊艷茹1*，劉景景1，李芳芳1，陳美華1，王 浩1，王 蕾1，孫立立1，王鳳澤2，王德才1，張漢霆1，3

（泰山醫(yī)學院1.藥理學研究所，2.生命科學學院，山東泰安 271016；3.Departments of Behavioral Medicine&Psychiatry and Physiology&Pharmacology，West Virginia University Health Sciences Center，Morgantown，WV 26506，USA）

目的 探討抗抑郁藥地昔帕明（DMI）對人腦膠質瘤耐藥細胞（U251/TR）對替莫唑胺（TMZ）耐藥作用的影響及其機制。方法 DMI 20~80 μmol·L-1或TMZ 0.5~10 mmol·L-1處理U251/TR細胞24 h，用CCK-8法測定DMI和TMZ對U251/TR細胞增殖抑制的半數(shù)有效量（IC50）。CCK-8檢測TMZ（1和2 mmol·L-1）和DMI（20，30和40 μmol·L-1）聯(lián)合或單獨處理U251/TR細胞24 h對細胞增殖抑制的影響，用金正均法計算Q值來評價兩種藥物的協(xié)同效應。TMZ（1 mmol·L-1）和DMI（30 μmol·L-1）聯(lián)合或單獨處理U251/TR細胞24 h，以Hoechst33258染色觀察細胞核形態(tài)，發(fā)光法檢測胱天蛋白酶3活性；實時定量PCR和Western蛋白印跡法檢測C/EBP同源蛋白（CHOP）的表達；小干擾RNA（siRNA）沉默CHOP的表達后，觀察TMZ（1 mmol·L-1）和DMI（30 μmol·L-1）聯(lián)合給藥對U251/TR增殖抑制的影響。結果 DMI或TMZ單用對U251/TR細胞增殖均有明顯的抑制作用，并且呈濃度依賴性（r2=0.983，0.982，P<0.05），IC50分別為（33.6± 0.5）μmol·L-1和（2.5±0.6）mmol·L-1。TMZ（1和2 mmol·L-1）和DMI（20，30和40 μmol·L-1）聯(lián)合給藥能24 h對U251/TR細胞的增殖抑制率明顯強于單獨給藥，以金正均法計算聯(lián)合給藥的Q值均>1.15，證實TMZ和DMI聯(lián)合給藥具有協(xié)同效應。同時，DMI 30 μmol·L-1和TMZ 1 mmol·L-1聯(lián)和應用可誘導U251/TR細胞凋亡，主要表現(xiàn)為細胞核固縮、染色質沉積和胱天蛋白酶3的激活。這種凋亡誘導作用明顯好于單獨給藥的效果（P<0.05）。DMI和TMZ聯(lián)合應用能顯著激活細胞內質網應激標志蛋白CHOP的表達（P< 0.05）。以siRNA沉默CHOP表達后，DMI逆轉TMZ耐藥的作用明顯減弱，聯(lián)合給藥組細胞生存率由51.8%升至62.2%（P<0.05）。結論 DMI能逆轉人腦膠質瘤細胞U251/TR對TMZ的耐藥性，其機制可能與激活CHOP表達有關。

腦膠質瘤；地昔帕明；替莫唑胺；逆轉耐藥；C/EBP同源蛋白

國家自然科學基金項目（81302202）；國家自然科學基金項目（81272683）；國家自然科學基金項目（81441111）；山東省自然科學基金項目（ZR2011HQ055）；山東省政府“泰山學者海外特聘專家”專項基金

張漢霆，E-mail：hzhang@hsc.wvu.edu，Tel：（0538）6231386

2016-04-20接受日期：2016-06-14）

R966

:A

:1000-3002-(2016)06-0620-07

10.3867/j.issn.1000-3002.2016.06.002

Foundation item:The project supported by National Natural Science Foundation of China(81302202);National Natural Sci?ence Foundation of China(81272683);National Natural Science Foundation of China(81441111);Natural Science Foundation of Shandong Province(ZR2011HQ055);and the Foundation of Overseas Distinguished Taishan Scholars of Shandong Province

Biography:MA Jian(1980-),female,associate professor,PhD,the main research field is tumor pharmacology;YANG Yan-ru(1990-),female,postgraduate,the main research field is tumor pharmacology.

Han-ting ZHANG,Tel:(0538)6231386,E-mail:hzhang@hsc.wvu.edu

*Co-first author.

*共同第一作者。

（本文編輯：喬 虹）